IMUC (EOM Pharmaceutical Holdings) OCF Yield %: -66.39 (As of Jul. 29, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is EOM Pharmaceutical Holdings OCF Yield %?

EOM Pharmaceutical Holdings IMUC OCF Yield % is -66.39 as of Jul. 29, 2026.

OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

As of today, EOM Pharmaceutical Holdings's Trailing 12-Month Cash Flow from Operations is $-10.93 Mil, and Market Cap is $16.46 Mil. Therefore, EOM Pharmaceutical Holdings's OCF Yield % for today is -66.39%.

The historical rank and industry rank for EOM Pharmaceutical Holdings's OCF Yield % or its related term are showing as below:

IMUC' s OCF Yield % Range Over the Past 10 Years
Min: -323.54   Med: 0   Max: -31.99
Current: -66.39


During the past 13 years, the highest OCF Yield % of EOM Pharmaceutical Holdings was -31.99%. The lowest was -323.54%. And the median was %.

IMUC's OCF Yield % is not ranked
in the Biotechnology industry.
Industry Median: -8.745 vs IMUC: -66.39

EOM Pharmaceutical Holdings's OCF Margin % for the quarter that ended in Jun. 2018 was %.


EOM Pharmaceutical Holdings OCF Yield % Explanation

Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


EOM Pharmaceutical Holdings OCF Yield % Related Terms


EOM Pharmaceutical Holdings OCF Yield % Historical Data

* Premium members only.

The historical data trend for EOM Pharmaceutical Holdings's OCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

EOM Pharmaceutical Holdings OCF Yield % Chart

EOM Pharmaceutical Holdings Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
OCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -16.49 -21.40 -59.28 -281.68 -125.89

EOM Pharmaceutical Holdings Quarterly Data
Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18
OCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -457.19 -99.80 -148.87 -61.20 -79.84

IMUC vs MNTMD, RTTR, BZYR: OCF Yield % Comparison

For the Biotechnology subindustry, EOM Pharmaceutical Holdings's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EOM Pharmaceutical Holdings OCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EOM Pharmaceutical Holdings's OCF Yield % distribution charts can be found below:

* The bar in red indicates where EOM Pharmaceutical Holdings's OCF Yield % falls into.



EOM Pharmaceutical Holdings OCF Yield % Calculation

OCF Yield % is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

EOM Pharmaceutical Holdings's OCF Yield % for the fiscal year that ended in Dec. 2017 is calculated as

OCF Yield %=Cash Flow from Operations / Market Cap
=-16.672 / 13.24356
=-125.89%

EOM Pharmaceutical Holdings's annualized OCF Yield % for the quarter that ended in Jun. 2018 is calculated as

OCF Yield %=Cash Flow from Operations * Annualized Factor / Market Cap
=-2.174 * 4 / 10.892409
=-79.84%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Yield % →
What does a OCF Yield % of -66.39 mean?
EOM Pharmaceutical Holdings (IMUC) has a OCF Yield % of -66.39 as of Jul. 29, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on EOM Pharmaceutical Holdings and its competitors.
Is EOM Pharmaceutical Holdings' OCF Yield % too high?
EOM Pharmaceutical Holdings' current OCF Yield % is -66.39.
How does EOM Pharmaceutical Holdings' OCF Yield % compare to MNTMD and RTTR?
EOM Pharmaceutical Holdings' OCF Yield % of -66.39 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on EOM Pharmaceutical Holdings and its competitors. EOM Pharmaceutical Holdings's current OCF Yield % is -66.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EOM Pharmaceutical Holdings stock overvalued right now?
EOM Pharmaceutical Holdings (IMUC) has a current OCF Yield % of -66.39. The current OCF Yield % is -66.39. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For EOM Pharmaceutical Holdings (IMUC), the current OCF Yield % is -66.39 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

EOM Pharmaceutical Holdings Business Description

Address 136 Summit Avenue, Suite 100, Montvale, NJ, USA, 07645
EOM Pharmaceutical Holdings Inc is a clinical-stage biotechnology company that is focused on developing drugs with the potential to transform therapeutic paradigms and improve quality of life in patients suffering from debilitating and sometimes deadly diseases. Its products have been approved in the U.S., rheumatoid arthritis, and inflammatory conditions of the gastrointestinal tract such as Crohn's Disease and Ulcerative Colitis as well as various retina disorders characterized by a breakdown of the blood-retinal barrier such as diabetic retinopathy, Aged related macular degeneration and retinal vein occlusion among others. Its pipeline includes its compound EOM613, an investigational novel dynamically dual-acting immunomodulator.